
Job Description

NIHR Academic Clinical Fellowship

Clinical or Medical Oncology - ST1 entry

(1 single speciality post)

Hull York Medical School, in partnership with NHS England North East and Yorkshire and the Hull University Teaching Hospitals NHS Trust, has developed an exciting pathway of academic clinical training opportunities.

Applications are now invited for an Academic Clinical Fellowship in **Clinical or Medical Oncology** at **ST1** level. This post is funded and approved by the National Institute for Health Research in the Clinical Therapeutics theme and offers candidates a comprehensive experience of clinical academic medicine working alongside internationally renowned clinicians and researchers.

We are seeking a highly motivated, enthusiastic individual with the potential to excel in both their clinical and academic training and who has the ambition to be the next generation of academic clinicians.

This Academic Clinical Fellowship (ACF) programme in Oncology is run by Hull York Medical School (HYMS) in conjunction with the Hull University Teaching Hospitals NHS Trust and NHS England North East and Yorkshire and the Humber.

Academic Clinical Fellowships (ACFs) are 3 year fixed-term national training posts. Trainees undertake 75% clinical and 25% academic training over the term of the post. They are employed by the NHS Trust and have an honorary contract with the University at whose Medical School their academic research is supported.

ACF trainees also undertake a Research Training Programme provided by the University. They are eligible for a £1,000 bursary per year to support research training activity (e.g. to attend academic conferences).

ACF trainees would also normally complete and submit an external funding application for a research fellowship to enable them to complete a higher degree (PhD or research MD) following the completion of their ACF fixed-term post, which would be completed as Out-of-Programme-Research (OOPR).

All Academic Clinical Fellowships are run-through posts. A trainee entering ACF at ST1 in a specialty with a Core Training period would therefore be guaranteed continued training to CCT in the eventual specialty, as long as they progress satisfactorily through both their

academic and clinical training. Run-through status is withdrawn if ACFs do not complete the academic component.

POST DETAILS

Job Title

NIHR Academic Clinical Fellow (ACF) – Oncology

Duration of the Post

Up to 3 years (25% academic, 75% clinical).

A mutually agreeable timetable will be drawn up by the candidate and the academic/clinical supervisors, designed to meet overall training goals. This will include protected research time. The exact division of time will be guided by the proposed research project and whether blocks of time or weekly research time are more appropriate. The appointee will have on-call commitments which will vary depending upon the varying shift systems and training/service requirements.

Lead NHS Hospital/Trust in which training will take place

Hull University Teaching Hospitals NHS Trust (see details of rotation below).

Research institution in which training will take place

The successful candidate will be based at the Centre of Biomedicine (in the new £28 million Allam Research Building, Hull York Medical School and University of Hull), and with our NHS partner – Hull University Teaching Hospitals NHS Trust (Castle Hill Hospital site, based in the Queen's Centre, Castle Hill Hospital, Hull). The Fellow will be supervised by Professor Anthony Maraveyas (Professor and Consultant in Oncology, Hull York Medical School and Hull University Teaching Hospitals NHS Trust) and Dr Leonid Nikitenko (Lecturer in Biomedical Sciences, Hull York Medical School, Faculty of Health Sciences, University of Hull).

Research Protected Time:

ACFs have protected time to attend and complete either an MSc by research or take relevant modules to extend their training (if they already have an MSc), at Hull York Medical School, if deemed appropriate. The protected research period (25% time) is used to obtain specific experience and knowledge in the research area of interest, obtain pilot data, and apply for an external research fellowship.

Academic Clinical Fellowship Training Programme: Research Component

This ACF post is funded by NIHR under the Platform Science and Bioinformatics theme.

This proposed Oncology ACF has the opportunity to research molecular pathways in PDAC (pancreatic ductal adenocarcinoma) in the Platform Science theme, using platform techniques such as:

1. next generation-sequencing, including single cell RNA sequencing (scRNAseq);

2. high throughput imaging/microscopy;
3. quantitative proteomics, including liquid chromatography with tandem mass spectrometry (LC-MS/MS) and multiplex antibody arrays;
4. bio(medical)informatics analysis using the University of Hull's High Performance Computer (HPC) VIPER.

These currently active strands within the research group will readily underpin a PhD Fellowship application on: (i) diagnosis and detection of early PDAC/malignant changes during carcinogenesis, e.g. epithelial to mesenchymal transition, using liquid biopsies (pancreatic cystic fluid/PCyF, blood/serum and urine; collected during prospective TEM-PAC study MREC: NCT03536793 & amendments) and multi-omics approach or (ii) molecular mechanisms of PDAC perineural invasion (by currently studying the role of cellular signalling via G-protein coupled receptor); with both being a particularly novel concepts, where the group is working at the cutting edge in the field. .

There is urgent need to improve early diagnosis and treatment of pancreatic cancer, which is closely linked to low socio-economic status and poor environs prevalent in Hull. The Cancer Research Group promotes translational research to tackle one of the highest incidences and poorest mortality rates from cancer nationally. It has pioneered the development of a Global Data, Platform Science and Bioinformatics theme in Hull (since 2017), using the state-of-the-art infrastructure of HPC VIPER and next generation sequencing equipment, and utilised it for discovering the proteomic signatures of the malignant transformation in PCyF, with follow-up studying using serum and urine to be done for validation and development of non-invasive diagnostic tests. There is also substantial progress towards micro-dissecting neuro-lymphatic-cancer/malignant cell crosstalk using these platform technologies, especially using scRNAseq and high throughput and confocal imaging/microscopy, and making advantage of the collection of pancreatic neoplasm and cancer tissues (FFPE samples at Royal Free Histopathology and frozen samples from TEMPAC tissue bank). Therefore, there is a substantial scope for contributing to research in both strands. Full training in research methods and techniques, and including good clinical practice, will be provided. ACF will gain immersive experience in human cell and cancer biology research, transcriptomics and bio(medical)informatics analysis through this and the wider body of work of the research group, including national collaborations (e.g. Target Discovery Institute, University of Oxford, Cancer Institute, University College London and University of Glasgow.), and will be also supported to present their research in national and international conferences.

Please contact Prof Anthony Maraveyas for further details (anthony.maraveyas@nhs.net)

On appointment, in conjunction with their supervisors, the ACF will complete a Training Needs Analysis (TNA) and be able to access modules from the HYMS Post Graduate Training Selection list both to help with their research project and with their professional development as a researcher.

We anticipate the successful exit point for ACF trainees will be the award of an externally funded clinical research training fellowship to pursue a PhD or MD; prior to re-joining the academic career path as a Clinical Lecturer.

Academic Clinical Fellowship Training Programme: Clinical Component

ST1 entrants will undertake their core medical training in Yorkshire and the Humber (North and East rotation). This is an excellent training area, with a fantastic mix of world leading hospitals, a forward-thinking training programme, with years of experience of incorporating simulation, and a well-developed trainee engagement programme. Significant investment in

PACES preparation has led to continuous year-on-year improvement in MRCP (UK) pass rates. Further details of the training programme are available at

https://heeyh-deanery-live.azurewebsites.net/medicine/core_medical_training

They will subsequently join the Yorkshire and Humber Oncology training rotation (East), and rotate through posts in tertiary and district general hospitals to gain a wide range of haematology experience. Comprehensive training in clinical and laboratory haematology is provided throughout.

Further details are available at

www.yorksandhumberdeanery.nhs.uk/medicine/haematology/home

CONTACTS

Academic Leads and Supervisors:

Prof Anthony Maraveyas

Professor and Consultant in Oncology at Hull York Medical School

anthony.maraveyas@nhs.net

Dr Leonid Nikitenko

Lecturer in Biomedical Sciences at Hull York Medical School

l.nikitenko@hull.ac.uk

Clinical Training Programme Directors

Medical Oncology: Dr Jane Hook

jane.hook@nhs.net

Clinical Oncology: Dr Michael Flatley

michael.flatley@nhs.net

Academic Training Programme Director

Professor Bob Phillips

Academic Training Programme Director

bob.phillips@york.ac.uk

Further Information

Because of the nature of the work for which you are applying, this post is exempted from the provisions of Section 4 (2) of the Rehabilitation of Offenders Act 1974 by virtue of the Rehabilitation of Offenders Act 1974 (Exceptions) Order 1975.

Applicants are therefore, not entitled to withhold information about convictions, which for other purposes are “spent” under the provisions of the Act, and in the event of employment any failure to disclose such convictions could result in dismissal or disciplinary action by the University. Any information given will be strictly confidential and will be considered only in relation to an application for positions to which the Order applies.

For further information about the Academic Clinical Fellowship programme, please refer to the NIHR (National Institute for Health Research) Trainee Coordinating Centre (NIHRTCC) page on [NIHR Integrated Academic Training For Doctors and Dentists - Academic Clinical Fellowships](#)

Person Specifications

All applicants who do not already hold a National Training Number (NTN) or Deanery Reference Number (DRN) in the GMC specialty to which they are applying for will be required to undertake the national clinical recruitment process and attend an assessment/interview for that GMC specialty as appropriate.

Trainees who hold a Deanery Reference Number in the penultimate year of Internal Medical Training (CT2) or ACCS acute medicine (CT3) are eligible to apply. Trainees who have either: completed Core Medical Training, IMT training or ACCS AM, are in the final year of IMT or ACCS AM, or have alternative experience outside of UK training, are not eligible to apply.

Trainees currently in the penultimate year of their core programme who are successful in gaining an ST3 level ACF programme will start their first year by completing IMY3. Assuming internal medicine stage 1 is completed successfully, they will then run through into their higher specialty at ST4 level. There is no requirement for trainees in this category to clinically benchmark as they will be carrying on with completing their IMT programme

See <http://specialtytraining.hee.nhs.uk/Recruitment/Person-specifications>

AND the Academic eligibility criteria listed at:

<http://specialtytraining.hee.nhs.uk/Recruitment/Person-specifications>

Please note - (applicants applying for Surgical, Medical or Psychiatry specialties at ST3 or above may be required to consult the relevant Core Training person specification).

How to Apply

For more information about applying to ACF vacancies in NHS England North East and Yorkshire and the Humber please visit:-

http://www.yorksandhumberdeanery.nhs.uk/recruitment/our_vacancies/academic_recruitment/

Applications will only be accepted through the Oriel online application system:-

<https://www.oriel.nhs.uk>

Applications open: Friday 6th October @ 10am

Applications close: Wednesday 1st November @ 4pm

After the application deadline no applications will be accepted. **There will be no exceptions to this deadline.** You are advised to complete and submit your application ahead of the deadline to allow for any unforeseen problems.

Interviews will be held online, date to be confirmed.

Appendix 1: Further particulars – Hull York Medical School

The Hull York Medical School (HYMS) is a collaboration between the Universities of Hull and York and the NHS. HYMS operates from both University campuses and within teaching hospitals and medical practices throughout the Yorkshire and Humber region. Having recently celebrated its 10th anniversary, HYMS is a relatively young medical school which is developing a growing reputation for its teaching and research.

HYMS has a strong reputation as an undergraduate medical school. Our innovative curriculum includes an enquiry-based approach to learning, early clinical experience, balanced teaching across all health sectors and a wide range of student selected learning opportunities. Our graduates are recognised as being very capable Foundation Doctors, many of whom have stayed locally to help develop health care services in this area.

The quality and impact on health and patient care of research carried out in the Hull York Medical School (HYMS) was recognised by the University of York's ranking as 7th in the country for Public Health, Health Services and Primary Care in the national Research Excellence Framework 2014. HYMS researchers were also part of York's top-10 rated submissions in Biology and Psychology. Across the whole of HYMS, a partnership between the Universities of Hull and York, over 85% of research was assessed as world leading or internationally excellent.

Within the Universities, research development in HYMS has been based on a distributed model, in which academic staff may have a research base in a cognate academic department of the University of Hull and/or York, providing scientific integration, critical mass and technology platforms with which to work. In relation to clinically orientated research there is a Clinical Research Facility (the Daisy Building) in Hull at Castle Hill Hospital and an Experimental Medicine Unit at York Hospital, to facilitate translational research. HYMS also plays a role in establishing and facilitating research networking between NHS partners in the region through topic based regional meetings.

The area covered by the HYMS NHS partnership comprises Hull and the East Riding of Yorkshire, York and North Yorkshire, and Northern Lincolnshire, which together have a population of around 1.8 million. 17 NHS organisations make up the HYMS NHS partnership, within which there are over 600 consultants and 900 general practitioners. Encompassing both rural and urban populations, the region contains a variety of environments in which health services are delivered. There are areas of considerable deprivation, not only in urban centres, but also in patches across the rural hinterlands. Heart disease and lung cancer are severe problems in Hull. Measures of overall health in North Lincolnshire are poorer than the country as a whole. However, in most of the region, rates for infant mortality and most disease-specific death are well below national averages, the prevalence of smoking and drug use are low, and the uptake of screening is high in many areas.

East Yorkshire with its homogenous and stable population of 600,000 is an ideal centre for prospective observational and interventional clinical research: the central urban area of Kingston upon Hull has a population of 350,000. The NHS clinical facilities are well developed and virtually comprehensive across the medical and surgical disciplines; only certain transplantation and cardiac neonatal surgical procedures require distant referral. Hence there exists a wealth of clinical material available for approved educational and research purpose.